Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 7, 1996, Pages 1720-1721

  Hook III, Edward W ^a,b,d   Pinson, Gloria B ^a   Blalock, Carol J ^a   Johnson, Raymond B ^c  

^a University of Alabama at Birmingham   (United States)

^b Jefferson County Department of Health   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TROVAFLOXACIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; GONORRHEA; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029948139     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.7.1720     Document Type: Article

References (13)

1. Centers for Disease Control and Prevention. 1993. Sexually transmitted diseases treatment guidelines. Morbid. Mortal. Weekly Rep. 42:56-65.
2. Centers for Disease Control and Prevention. 1995. Sexually transmitted disease surveillance, 1994. Centers for Disease Control and Prevention, Atlanta.
3. Centers for Disease Control and Prevention. 1995. Fluoroquinolone resistance in Neisseria gonorrhoeae - Colorado and Washington, 1995. Morbid. Mortal. Weekly Rep. 44:761-764.
4. Grenier, B. 1992. Use of fluoroquinolones in children. An overview. Adv. Antimicrob. Antineoplast. Chemother. 11:135-140.
5. Hook, E. W., III, R. B. Jones, D. H. Martin, G. A. Boland, T. F. Mroczkowski, T. M, Neumann, J. J. Haag, and R. Echols. 1993. Comparison of ciprofloxacin and ceftriaxone as single-dose therapy for uncomplicated gonorrhea in women. Antimicrob. Agents Chemother. 37:1670-1673.
6. Knapp, J. S., S. W. Neal, M. C. Parekh, and R. J. Rice. 1995. In vitro activity of a new fluoroquinolone, CP-99,219 against strains of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 39:987-989.
7. Martin, D. H., R. B. Jones, and R. B. Johnson. 1995. A phase II study of CP-99,219-27 for the treatment of Chlamydia trachomatis infections, abstr. LM33, p. 332. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Nuutinen, M., J. Turtinen, and M. Uhari. 1994. Growth and joint symptoms in children treated with nalidixic acid. Pediatr. Infect. Dis. J. 13:798-800.
9. Pfizer Central Research, Groton, Conn. Data on file.
10. Reichart, C. A., T. Neumann, P. Foreman, J. M. Zenilman, and E. W. Hook III. 1992. Temporal trends in gonococcal antibiotic resistance in Baltimore. Sex. Transm. Dis. 19:213-218.
11. Schwarcz, S. K, J. M. Zenilman, D. Schnell, J. S. Knapp, E. W. Hook III, S. Thompson, F. N. Judson, and K. K. Holmes. 1990. The gonococcal isolate surveillance project. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. JAMA 264:1413-1417.
12. Van Der Pol, B., and R. B. Jones. 1995. In vitro activity of CP-99,219 against Chlamydia trachomatis, abstr. F237F, p. 154. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Whittington, W. L., and J. S. Knapp. 1988. Trends in resistance of Neisseria gonorrhoeae to antimicrobial agents in the United States. Sex. Transm. Dis. 15:202-210.